Repligen Corp. Rating Lowered to Neutral at Zacks (RGEN)
Repligen Corp. (NASDAQ:RGEN) was downgraded by Zacks to a “neutral” rating in a report released on Monday. They currently have a $23.80 target price on the stock. Zacks‘s price target points to a potential upside of 5.12% from the stock’s previous close.
Shares of Repligen Corp. (NASDAQ:RGEN) traded up 0.35% on Monday, hitting $22.72. The stock had a trading volume of 202,835 shares. Repligen Corp. has a 52 week low of $8.25 and a 52 week high of $22.98. The stock has a 50-day moving average of $19.74 and a 200-day moving average of $15.69. The company has a market cap of $727.9 million and a P/E ratio of 40.50.
Repligen Corp. (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.13 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.07 by $0.06. The company had revenue of $16.33 million for the quarter, compared to the consensus estimate of $15.14 million. Repligen Corp.’s revenue was down .8% compared to the same quarter last year. On average, analysts predict that Repligen Corp. will post $0.29 earnings per share for the current fiscal year.
RGEN has been the subject of a number of other recent research reports. Analysts at Janney Montgomery Scott initiated coverage on shares of Repligen Corp. in a research note on Thursday. They set a “buy” rating and a $26.00 price target on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Repligen Corp. from $20.00 to $22.00 in a research note on Wednesday, June 4th. They now have a “buy” rating on the stock. Finally, analysts at Jefferies Group initiated coverage on shares of Repligen Corp. in a research note on Tuesday, April 15th. They set a “buy” rating and a $17.00 price target on the stock.
In other Repligen Corp. news, Director Thomas F. Ryan, Jr. sold 10,000 shares of Repligen Corp. stock on the open market in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $21.78, for a total value of $217,800.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Repligen Corporation is a United States-based life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.